RAMM Pharma Corp.
RAMM
CNSX
| 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -41.64% | -27.13% | -28.92% | 0.47% | -11.57% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -41.64% | -27.13% | -28.92% | 0.47% | -11.57% |
| Cost of Revenue | -73.89% | 49.94% | -12.45% | 6.11% | -73.20% |
| Gross Profit | -10.74% | -99.93% | -62.15% | -15.46% | 173.41% |
| SG&A Expenses | -56.20% | -42.30% | -56.29% | -20.39% | 148.15% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -35.80% | -26.67% | -21.21% | -43.08% | -8.10% |
| Total Operating Expenses | -57.59% | -17.92% | -44.65% | -12.79% | 32.58% |
| Operating Income | 61.76% | 6.98% | 54.85% | 21.37% | -52.48% |
| Income Before Tax | 38.72% | 47.54% | 93.75% | 53.91% | -196.95% |
| Income Tax Expenses | 30.51% | -- | -- | -- | -16.90% |
| Earnings from Continuing Operations | 38.67% | 47.54% | 88.58% | 57.61% | -196.40% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 38.67% | 47.54% | 88.58% | 57.61% | -196.40% |
| EBIT | 61.76% | 6.98% | 54.85% | 21.37% | -52.48% |
| EBITDA | 63.93% | -14.19% | 56.92% | 15.59% | -60.82% |
| EPS Basic | 38.64% | 47.54% | 88.79% | 57.75% | -195.80% |
| Normalized Basic EPS | 34.67% | 44.74% | 65.67% | 31.67% | -40.19% |
| EPS Diluted | 38.64% | 47.54% | 88.79% | 57.75% | -195.80% |
| Normalized Diluted EPS | 34.67% | 44.74% | 65.67% | 31.67% | -40.19% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.02% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.02% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |